Literature DB >> 6607954

Monoclonal antibody SN2 defining a human T cell leukemia-associated cell surface glycoprotein.

B K Seon, S Negoro, M P Barcos, C K Tebbi, D Chervinsky, T Fukukawa.   

Abstract

We generated a monoclonal antibody, termed SN2, which defines a human T cell leukemia-associated cell surface glycoprotein, GP37, with an approximate m.w. of 37,000. This antibody was generated by using a human leukemia antigen preparation. The reactivity and specificity of SN2 were characterized by a sensitive radioimmunoassay against a variety of cultured and uncultured human cells. In selected cases, the cell specimens were tested further by indirect immunofluorescence staining. Among the various cultured malignant and nonmalignant human cell lines tested, SN2 reacted only with leukemic T cell lines, with one exception. It reacted with 10 of 11 leukemic T cell lines tested; the 10 reactive cell lines are PEER, JM, MOLT-4, CCRF-CEM, CCRF-H-SB2, RPMI 8402, DND-41, HPB-ALL, SKW-3, and HPB-MLT; the unreactive line was HUT 78. The reactive cell lines were derived from patients either with T cell-type acute lymphoblastic leukemia (the first eight cell lines), with T cell chronic lymphocytic leukemia (SKW-3), or with Japanese adult T cell leukemia-lymphoma (HPB-MLT). The unreactive cell line, HUT 78, was from a patient with Sezary syndrome. Results consistent with the above were obtained from studies in which uncultured malignant cell specimens from different cancer patients were tested against SN2; SN2 reacted only with T leukemia cells. Among various uncultured normal cell specimens tested, SN2 did not react with thymocytes, bone marrow cells, peripheral blood lymphocytes containing B and T cells, purified T cells, monocytes, granulocytes, or erythrocytes. It did, however, react with platelets.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6607954

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Expression of Pax5 gene in human haematopoietic cells and tissues: comparison with immunodeficient donors.

Authors:  H Kaneko; T Ariyasu; R Inoue; T Fukao; K Kasahara; T Teramoto; E Matsui; S Hayakawa; N Kondo
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

Review 2.  Idiotypic antibody immunotherapy of cancer.

Authors:  M B Chatterjee; K A Foon; H Köhler
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

3.  Effect of specific anti-human leukaemia immunotoxins on the colony formation by human haematopoietic progenitors and by human leukaemia cells.

Authors:  C K Tebbi; D Chervinsky; B K Seon
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

4.  Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.

Authors:  Y Haruta; B K Seon
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

5.  Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models.

Authors:  H Hara; B K Seon
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Idiotypic self binding of a dominant germline idiotype (T15). Autobody activity is affected by antibody valency.

Authors:  C Y Kang; H L Cheng; S Rudikoff; H Kohler
Journal:  J Exp Med       Date:  1987-05-01       Impact factor: 14.307

Review 7.  Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.

Authors:  Rimas J Orentas; Jessica Nordlund; Jianbin He; Sivasish Sindiri; Crystal Mackall; Terry J Fry; Javed Khan
Journal:  Front Oncol       Date:  2014-06-10       Impact factor: 6.244

8.  Tax contributes apoptosis resistance to HTLV-1-infected T cells via suppression of Bid and Bim expression.

Authors:  A Mühleisen; M Giaisi; R Köhler; P H Krammer; M Li-Weber
Journal:  Cell Death Dis       Date:  2014-12-18       Impact factor: 8.469

9.  ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.

Authors:  Felicia Leccia; Luigi Del Vecchio; Elisabetta Mariotti; Rosa Di Noto; Anne-Pierre Morel; Alain Puisieux; Francesco Salvatore; Stéphane Ansieau
Journal:  Mol Cancer       Date:  2014-09-12       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.